Welcome to our dedicated page for JUPITER NEUROSCIENCES news (Ticker: JUNS), a resource for investors and traders seeking the latest updates and insights on JUPITER NEUROSCIENCES stock.
Jupiter Neurosciences, Inc. develops JOTROL™, a patented resveratrol-based platform used in its clinical-stage neuroinflammation pipeline and Nugevia™ consumer longevity products. Company news centers on CNS and rare-disease development, including Parkinson’s disease work, and on commercialization of Nugevia formulations for mitochondrial support, cognitive health and skin vitality.
Recurring updates also cover investor-conference presentations, practitioner and wellness-channel initiatives, advisory-board additions, financing arrangements tied to convertible notes and a standby equity purchase agreement, and Nasdaq listing-compliance matters affecting its common stock.
Jupiter Neurosciences (NASDAQ:JUNS) closed a registered direct offering of 7,142,858 common shares, raising approximately $2.0 million in gross proceeds. The company indicates the capital extends cash runway for its Parkinson’s program, supports debt reduction, and funds its Phase 2a RESET trial of JOTROL in Parkinson’s disease.
Preclinical data showed statistically significant neuroprotective effects that supported an IND granted in November 2025.
Jupiter Neurosciences (NASDAQ:JUNS) priced a registered direct offering of 7,142,858 common shares, expected to raise approximately $2.0 million in gross proceeds. D. Boral Capital is exclusive placement agent, with closing targeted on or about May 21, 2026, under an effective Form S-3 shelf registration.
Jupiter Neurosciences (NASDAQ:JUNS) signed a $100 million term sheet for exclusive, perpetual U.S. rights to ALA-002, PharmAla Biotech’s next-generation MDMA therapeutic. Upfront consideration totals $3.33 million, split between $1.50 million cash and $1.83 million in JUNS shares, plus milestones and single-digit royalties.
Jupiter will escrow $600,000, usable as a reverse termination fee if no definitive agreement is signed within 90 days. ALA-002 is an FDA-recognized Novel Chemical Entity, designed for improved cardiovascular safety and reduced abuse liability versus racemic MDMA.
Jupiter Neurosciences (NASDAQ: JUNS) will present at the Market Movers Investor Summit on Tuesday, May 5, 2026 at 9:00 AM ET at 48 Wall Street (the original Bank of New York). Christer Rosén, chairman and CEO, will deliver the company presentation.
The summit runs May 4–5, 2026, and features company presentations, fireside chats, one-on-one meetings, and networking for public and private company executives, fund managers, and family offices. Invitation requests available via the summit website.
Jupiter Neurosciences (NASDAQ: JUNS) will present at the Centri Capital Conference on April 14, 2026 at Nasdaq in New York City. Christer Rosén, chairman and CEO, will discuss recent performance and future growth plans and participate in investor meetings and panel sessions.
The conference hosts presenting companies, fireside chats, facilitated 1:1 investor meetings and sponsors from the capital markets ecosystem.
Jupiter Neurosciences (NASDAQ: JUNS) appointed Kristopher Fishman and Sanjiv Lal to the Nugevia™ Advisory Board, adding direct distribution expertise across compounding pharmacies and wellness channels. The company cites an addressable U.S. nutraceutical market of over $1.5 billion. Nugevia™ uses JOTROL™ micellar delivery and includes three formulations: PWR, MND, and GLO. The JOTROL platform supports Jupiter’s clinical pipeline, including a Phase IIa Parkinson’s trial that received FDA clearance. Products are currently direct-to-consumer at the company website, and Jupiter is expanding into practitioner-led channels to leverage clinical-grade bioavailability data.
Jupiter Neurosciences (NASDAQ: JUNS) will present at Emerging Growth Conference 91 on April 2, 2026 at 10:15 AM ET to discuss clinical and commercial progress for JOTROL.
The live, interactive webcast is available via the conference link and an archived webcast will be posted on EmergingGrowth.com and the Emerging Growth YouTube channel after the event.
Jupiter Neurosciences (NASDAQ: JUNS) will present at the BIO Investment and Growth Summit 2026 on March 2, 2026 at 2:30 PM ET in Miami Beach. Management will discuss an FDA-cleared IND and the company’s ongoing Phase IIa Parkinson’s program and commercial progress with Nugevia.
Jupiter cites IND clearance in November 2025, preclinical JOTROL bioavailability improvements, repeat purchase rates ~25%, and ~3% return rates as early commercial validation.
Jupiter Neurosciences (NASDAQ: JUNS) was invited as the sole company to present progress at a private investor dinner on February 25, 2026 at Mar-a-Lago in Palm Beach. Management will update attendees on Phase IIa Parkinson’s progress, the neuroinflammation pipeline, and commercial execution of Nugevia™.
The event is invitation-only for accredited investors, organized by the Money Channel NYC, and management said it intends to continue direct investor engagement; contact ir@jupiterneurosciences.com for meeting requests.
Jupiter Neurosciences (NASDAQ: JUNS) entered an Omnibus Amendment with YA II PN, Ltd. that defers installment repayments to April 1, 2026 while keeping the $6.0 million core economic financing terms unchanged. The amendment modifies timing and application mechanics only and adds no new pricing, resets, or commitments.
Management says the change aligns capital timing with advancing its Phase II Parkinson’s program and scaling commercial sales of Nugevia (JOTROL resveratrol), which shows ~25% repeat purchases and ~3% returns. The company remains in compliance with its transaction documents.